Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23231154 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL17345123 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL20364750 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL2603329 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL13910210 | 1.00 | ALDH1A1 (0.36) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL20078451 | 0.98 | SLC18A3 (0.35) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL20696685 | 0.98 | SLC18A3 (0.35) | ALDH1A1CNR2HRH3HSD11B1SLC18A3 | |
| SCHEMBL2741649 | 0.95 | CNR2 (0.33) | ALDH1A1CNR2HRH3DRD2DRD3 | |
| SCHEMBL21477613 | 0.91 | HRH3 (0.33) | ALDH1A1HRH3 | |
| SCHEMBL21476719 | 0.91 | HRH3 (0.33) | ALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870661-B2 | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2020-12-22 | — | — | US | disclosed |
| US-20200055873-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2020-02-20 | — | — | US | disclosed |
| US-20180162876-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180162876-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| US-9975906-B2 | Tricyclic heterocycle derivatives having HIV replication inhibitory effect | SHIONOGI & CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9975906-B2 | Tricyclic heterocycle derivatives having HIV replication inhibitory effect | SHIONOGI & CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20170107234-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20170107234-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT | SHIONOGI & CO., LTD. (JP) | 2017-04-20 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2015-12-17 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-7888363-B2 | 1-Cyclopentyl-3-methyl-2-(2-pyridyl)indole-5-amino/thio/carbonyl derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-15 | — | — | US | disclosed |
| US-20070142380-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055873-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | NR4A3, CCR3, NCOA3 | ALDH1A1 4179/4885CNR2 622/4885HRH3 225/4885 |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ALDH1A1 355/4885CNR2 2545/4885HRH3 2143/4885 |
| US-20150361093-A1 | HIV REPLICATION INHIBITOR | RTF2, REV1, PCNA | ALDH1A1 4109/4885CNR2 2051/4885HRH3 213/4885 |
| US-20180162876-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | NR4A3, CCR3, NCOA3 | ALDH1A1 4179/4885CNR2 622/4885HRH3 225/4885 |
| US-20170107234-A1 | TRICYCLIC HETEROCYCLE DERIVATIVES HAVING HIV REPLICATION INHIBITORY EFFECT | NR4A1, NR4A3, NR0B1 | ALDH1A1 2707/4885CNR2 357/4885HRH3 790/4885 |
| US-10870661-B2 | Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity | NR4A3, CCR3, NCOA3 | ALDH1A1 4179/4885CNR2 622/4885HRH3 225/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ALDH1A1 355/4885CNR2 2545/4885HRH3 2143/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | ALDH1A1 355/4885CNR2 2545/4885HRH3 2143/4885 |
| US-20070142380-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | ALDH1A1 1556/4885CNR2 4428/4885HRH3 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.